RecruitingPhase 2

A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Switzerland30 participantsStarted 2014-12

Plain-language summary

To assess the feasibility of donor-derived interferon (IFN)-γ positive select-ed virus-specific T-cells using the cytokine capture system® (CCS) and the safety of subsequent infusion in recipients of hematopoietic stem cell transplantation (HSCT) with treatment refractory post-transplant viral infections. The CCS has already been successfully used in clinical studies in Germany and United Kingdom (UK).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Antiviral treatment with cidofovir for at least 7 days
✓. Or if antiviral treatment is contraindicated
✓. Antiviral treatment with ganciclovir or foscavir for 14 days
✓. Or if \> 2 recurrences despite antiviral treatment with ganciclovir or foscavir for 14 days and CD3+ cells \< 300/µL
✓. Or if antiviral treatment is contraindicated -

What they're measuring

Level of enriched IFN-γ+ T-cells

Timeframe: 7 days

Trial details

NCT IDNCT02007356

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Nina Khanna, MD

+41-61-2652525 (Zentrale) nina.khanna@usb.ch

View on ClinicalTrials.gov More Adenovirus Infection trials